Key facts
- NEUmiRNA’s last known valuation is $31.1M (Jan 2025).
- It has raised $24.5M; the latest was Later Stage VC ($23.3M) in Jan 2025.
- Notable investors include Innovestor, Angelini Ventures, Invivo Partners, Michael J. Fox Foundation, Sunstone Life Science Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for NEUmiRNA
- ·The full record, as it builds
Funding rounds
No funding rounds for NEUmiRNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NEUmiRNA
Developer of ribonucleic acid therapies designed to treat neurological disorders. The company provides anti-miRNA treatment for transformative disease modification for neurological conditions, enabling healthcare professionals to treat patients suffering from epilepsy.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2020
- Employees
- 12
- Website
- neumirna.com/
- Ownership
- Privately Held (backing)
NEUmiRNA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NEUmiRNA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NEUmiRNA in its N-PORT filings yet. We sweep new filings monthly.